Status:
ENROLLING_BY_INVITATION
Biological Changes Associated With High Risk of Preeclampsia in Nulliparous Women
Lead Sponsor:
Norwegian University of Science and Technology
Collaborating Sponsors:
Alesund Hospital
St. Olavs Hospital
Conditions:
Preeclampsia
Eligibility:
FEMALE
18+ years
Brief Summary
Primary outcome 1. to identify biological changes in nulliparous women at high risk for preeclampsia defined by combined screening by Fetal Medicine Foundation (FMF) 2. to identify biological effects...
Detailed Description
St. Olavs Hospital offers FMF-screening in week 11-14 and aspirin treatment through the "Implementing Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks - a Randomized Co...
Eligibility Criteria
Inclusion
- 18 years or older
- nulliparous women
- singleton live fetus
- FMF risk \> 1/100 (high risk), or \< 1/150 (low risk)
Exclusion
- not speaking Norwegian or English language
- fetal anomalies diagnosed with ultrasound
Key Trial Info
Start Date :
May 22 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2032
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06200571
Start Date
May 22 2024
End Date
December 31 2032
Last Update
December 12 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Alesund Hospital
Ålesund, Norway, 6017
2
St. Olavs Hospital
Trondheim, Norway, 7030